<DOC>
	<DOCNO>NCT00028327</DOCNO>
	<brief_summary>Many HIV infect patient admit intensive care area ( ICA ) never take anti-HIV drug . The purpose study learn whether start anti-HIV drug patient ICA help survive get good faster . This study also evaluate patient , though ICA , admit hospital serious illness infection .</brief_summary>
	<brief_title>Potent Antiviral Therapy Critically Ill HIV Infected Patients Admitted Intensive Care</brief_title>
	<detailed_description>There considerable debate management HIV infect individual admit ICA . Mortality HIV infect patient ICA correlate level immune suppression . The majority HIV infect individual enter ICA antiretroviral naive . Despite high mortality rate opportunity intervene antiretroviral therapy , physician routinely administer highly active antiretroviral therapy ( HAART ) ICA . Early initiation HAART , improve immune function , could potentially reduce mortality . Numerous study show dramatic drop HIV-1 RNA level accompany increase CD4 cell count within first 2 4 week therapy . Sufficient data exist antiretrovirals could administer ICA careful monitoring attention drug interaction . This study evaluate effect HAART patient admit hospital AIDS-defining illness , pneumonia , sepsis . Upon entry study , patient stratify accord severity illness score ( SAPS I ) CD4 cell count . Patients assign 1 2 study arm : Arm A : HAART ( lamivudine [ 3TC ] zidovudine [ ZDV ] , 3TC/ZDV , nelfinavir [ NFV ] efavirenz [ EFV ] ) ; alternative HAART 4 week . Arm B : No antiretroviral regimen . Evaluations follow perform : drug toxicity , immune status , viral load , arterial blood gas , ventilator parameter , evolution present illness . Pharmacokinetic trough concentration analysis perform patient Arm A 3 time point illness . Patients follow 24 week entry . Patients Arm A may elect participate two substudies . The first substudy measure efavirenz nelfinavir drug level blood determine critical illness affect pharmacokinetics . The second substudy evaluate benefit HAART HIV infect patient treat pneumocystis carinii pneumonia .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>Inclusion Criteria HIV1 infection CD4 cell count le 350 cells/mm3 within 120 hour prior study entry Admission ICA ( part hospital arterial blood gas PaO2/FiO2 ratio &lt; 200 SAPS I score &gt; 13 ) within 120 hour prior study entry Admitted hospital sepsis , pneumonia , AIDSdefining disease Acceptable method contraception Exclusion Criteria Known resistance intolerance antiretroviral drug precludes use effective HAART regimen FDA approve drug , exclude abacavir fulldose ritonavir More 7 day HAART ( regimen least 3 drug include protease inhibitor , nonnucleoside reverse transcriptase inhibitor , three nucleoside analogue ) within 4 week prior study entry Investigational drug within 14 day prior study entry Pregnant breastfeeding Allergy sensitivity study drug substitute another drug CNS mass lesion bacterial meningitis Certain medication Uncertain availability 6 month course study Require regular stomach suctioning</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2004</verification_date>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>CD4 Lymphocyte Count</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Pneumonia</keyword>
	<keyword>Nelfinavir</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Antiretroviral Therapy , Highly Active</keyword>
	<keyword>Efavirenz</keyword>
	<keyword>Intensive Care Units</keyword>
	<keyword>Sepsis</keyword>
</DOC>